Comparison of Long-Term Outcomes After Percutaneous Coronary Intervention in Patients With Insulin-Treated Versus Non-Insulin Treated Diabetes Mellitus.
Aged
Angina, Stable
/ epidemiology
Angina, Unstable
/ epidemiology
Atherectomy, Coronary
Comorbidity
Coronary Artery Disease
/ epidemiology
Diabetes Mellitus
/ drug therapy
Drug-Eluting Stents
Female
Humans
Hypoglycemic Agents
/ therapeutic use
Insulin
/ therapeutic use
Male
Middle Aged
Non-ST Elevated Myocardial Infarction
/ epidemiology
Percutaneous Coronary Intervention
Prognosis
ST Elevation Myocardial Infarction
/ epidemiology
Stroke Volume
Ventricular Dysfunction, Left
/ epidemiology
Journal
The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
received:
11
11
2020
revised:
17
02
2021
accepted:
23
02
2021
pubmed:
6
3
2021
medline:
20
7
2021
entrez:
5
3
2021
Statut:
ppublish
Résumé
There are conflicting data on whether patients with insulin-treated diabetes mellitus (ITDM) have poorer outcomes compared with non-insulin treated diabetic (non-ITDM) patients following percutaneous coronary intervention (PCI). We therefore compared clinical outcomes following PCI in ITDM versus non-ITDM patients. We prospectively collected data on 4,579 patients with diabetes underwent PCI between 2005 and 2014 in a large multicenter registry and dichotomized them as having ITDM (n = 1,111) or non-ITDM (n = 3,468). The non-ITDM group was further divided into diet control only (diet-DM; n = 786) and those taking oral hypoglycemic agents (OHG-DM; n = 2,639), and clinical outcomes were compared with ITDM patients. Median follow-up for long-term mortality was 4.2 years (IQR 2.0 to 6.6 years). ITDM patients were more likely to be female, obese, and have severe renal impairment (all p <0.001). Procedural characteristics were similar other than a greater use of drug-eluting stents in ITDM patients. On multivariable analysis, ITDM was an independent predictor of 12-month major adverse cardiovascular and cerebrovascular events (MACCE; OR 1.26, 95% CI 1.02 to1.55, p = 0.03). Dividing the non-ITDM group further by treatment, a progressively higher rate of 12-month MACCE across the 3 groups was observed (13.5% vs 17.9% vs 21.8%; p <0.001). Long-term mortality was similar in the diet-DM and OHG-DM groups, but significantly higher in the ITDM group on Kaplan-Meier analysis (log-rank p <0.001). In conclusion, there is a clear gradient of adverse outcomes with escalation of therapy from diet control to OHGs to insulin.
Identifiants
pubmed: 33667454
pii: S0002-9149(21)00200-9
doi: 10.1016/j.amjcard.2021.02.025
pii:
doi:
Substances chimiques
Hypoglycemic Agents
0
Insulin
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36-43Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.